Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 19/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.61 |
| ▸ | ERBB4 | Q15303 | 6/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | MC3R | P41968 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.61 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17503009 | 1.00 | EGFR (0.63) | EGFRERBB2ERBB4JAK3GAK | |
| Bromide SCHEMBL868455 | 0.90 | EGFR (0.67) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL17503015 | 0.90 | EGFR (0.67) | EGFRERBB2ERBB4GAKRIPK2 | |
| Trifluoroacetic Acid SCHEMBL868626 | 0.88 | EGFR (0.64) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL17412737 | 0.87 | EGFR (0.61) | EGFRERBB2ERBB4JAK3GAK | |
| Bromide SCHEMBL868128 | 0.86 | EGFR (0.65) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL17503025 | 0.85 | EGFR (0.64) | EGFRERBB2ERBB4JAK3 | |
| Bromide SCHEMBL11902840 | 0.83 | EGFR (0.68) | EGFRERBB2ERBB4JAK3 | |
| Bromide SCHEMBL869044 | 0.82 | EGFR (0.82) | EGFRERBB2 | |
| Bromide SCHEMBL17817741 | 0.82 | EGFR (0.63) | EGFRERBB2ERBB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | claimed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | claimed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | claimed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | claimed |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | RAIN THERAPEUTICS INC. | 2021-11-11 | — | — | US | disclosed |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2020-08-27 | — | — | US | disclosed |
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | CHRM1 892/4885EGFR 48/4885ERBB2 7/4885 |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | EGFR, BRCA1, ERBB2 | CHRM1 4628/4885EGFR 1/4885ERBB2 3/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | CHRM1 907/4885EGFR 41/4885ERBB2 7/4885 |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | EGFR, VHL, MYC | CHRM1 3391/4885EGFR 1/4885ERBB2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.